LOGIN  |  REGISTER
Compass Therapeutics

Quantum-Si to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 21, 2025 | Last Trade: US$1.44 0.03 -2.04

BRANFORD, Conn. / Jul 21, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the Canaccord Genuity 45th Annual Growth Conference taking place at the InterContinental Boston Hotel, August 12-14, 2025.

Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer will be taking one-on-one meetings throughout the day on Tuesday, August 12, 2025 and will participate in a fireside chat on the same day at 4:00 PM Eastern Time.

A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page